ShanghaiApril 28, 2026 /PRNewswire/ — Today, global leading biotechnology company CSL Behring attended the 2026 ChinaBio™ International Conference on Biomedical Industry Cooperation. Marking its 40th anniversary in the Chinese market, Dr. Stephen Pitt, Head of Global Opportunity Search and Evaluation at CSL Behring, participated in a panel discussion titled “New Collaboration Paradigm: From Asset Transactions to Ecosystem Alliances,” sharing CSL Behring’s long-term commitment to the Chinese market, insights into future collaboration models, and new ideas for local innovation partnerships.
Dr. Stephen Pitt, Head of Global Opportunity Search and Evaluation at CSL Behring
Dr. Stephen Pitt stated: “We deeply recognize that China holds extraordinary collaboration opportunities. Amid the rapid development of the global life sciences sector, collaboration models are shifting from traditional asset transactions to more ecosystem-oriented alliances. We look forward to partnering with innovative companies in China to drive breakthrough innovations and accelerate the delivery of novel therapies to patients worldwide.”
Four Decades Deep in China: From Introducing Global Innovation to Helping Local Achievements Reach the World
CSL Behring’s participation in this exhibition coincides with the company’s 40th anniversary of deep engagement in the Chinese market. Since introducing its first batch of human albumin to China in 1986, CSL Behring has been committed to serving patients with rare diseases and critical illnesses, becoming a trusted partner in China’s healthcare sector. In fiscal year 2025[1], the company has benefited over 4 million critically ill patients in China. In recent years, CSL Behring introduced its anti-D immunoglobulin[2] in the Greater Bay Area, benefiting approximately 4,000 Rh-negative pregnant women. Additionally, the new drug application for garadacimab, an innovative therapy for preventing hereditary angioedema (HAE) attacks, was submitted and accepted last year, continuing to fulfill its commitment to Chinese patients.
As a biotechnology company with a century-long history, CSL Behring invests $1.4 billion annually in R&D and offers over 60 marketed therapies and vaccines across more than 100 countries. Reflecting on its century of innovation, CSL Behring has expanded its global influence through a dual-drive approach of internal R&D and external innovation—including integrating a global leader in plasma and recombinant therapies to establish CSL Behring in 2004, founding CSL Seqirus in 2015, and acquiring Vifor in 2022, making it one of the top 20 biotech and pharmaceutical companies globally by revenue in 2025[3]. CSL Behring is dedicated to improving patients’ lives by addressing complex diseases in areas such as hematology, cardiovascular/renal diseases, immunology, and immunoglobulin therapy-related conditions.
Partnering with Chinese Allies for a Global Health Future
China is a global leader in biopharmaceutical innovation. Data shows that in 2025, China contributed approximately one-third of the global innovative pipeline assets, with about one-third being next-generation therapies.[4] The activity of licensing transactions in the Chinese market continues to rise, with regulatory reforms and the application of artificial intelligence in R&D further enhancing efficiency. Notably, China’s biotech innovation is showing strong momentum in fields such as immunology and cardiovascular diseases, which align closely with CSL Behring’s core therapeutic areas.
In recent years, CSL Behring has not only focused on introducing globally leading innovative therapies to China—such as the successful collaboration with Vifor Pharma to secure approval for Korsuva® in China, translating global R&D outcomes into meaningful clinical value for Chinese patients—but has also worked with local innovative companies and institutions to bring China’s cutting-edge science and breakthrough achievements to the global market. CSL Behring has established successful collaboration models with local partners like Baheal Pharmaceutical, further expanding access to innovative therapies.
“For Chinese biotech companies seeking global influence, CSL Behring brings not only capital support but also deep expertise in rare and serious diseases, global clinical development and commercialization networks, and proven experience in delivering innovative therapies to patients worldwide,” Dr. Pitt further noted. “We look forward to building deep connections with Chinese enterprises and institutions focused on rare and serious diseases in areas such as hematology, cardiovascular/renal, and immunology, to jointly accelerate global drug development.”
CSL Behring invites attendees of ChinaBio™ 2026, including potential partners, investors, and media friends, to explore future collaboration opportunities with us.
|
[1] Data period from July 1, 2024, to June 30, 2025. |
|
[2] Anti-D immunoglobulin is a special imported drug under the Hong Kong and Macau Drug and Device Connect policy, limited to use at the University of Hong Kong-Shenzhen Hospital, the First Affiliated Hospital of Sun Yat-sen University, and Shenzhen Bao’an District Maternal and Child Health Hospital. It has not been approved for marketing in other regions of mainland China. This product is a prescription drug; please consult clinical professionals for its use. This communication does not represent any clinical opinion or advice. |
|
[3]https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2025-revenue |
|
[4] McKinsey report “Building Bridges to Global Innovation” |